Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Who is Atanu Chakraborty? The man behind HDFC Bank’s Rs 1 lakh crore market cap wipeout
HDFC Bank’s share price plummeted by up to 9%, wiping out over Rs 1 lakh crore in market value following the resignation of its part-time